StockNews.AI
PACB
StockNews.AI
201 days

PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025

1. PacBio will hold its Q4 2024 earnings call on February 13, 2025. 2. The call can be accessed via webcast on PacBio's investor website. 3. PacBio specializes in advanced sequencing solutions for complex genetic issues. 4. Their technologies include HiFi long-read and SBB short-read sequencing. 5. PacBio products serve diverse research applications, from oncology to infectious diseases.

Earnings
-3.75%Current Return
VS
-0.51%S&P 500
$1.601/30 04:14 PM EDTEvent Start
$1.5401/31 10:28 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings call may provide insight into company performance without immediate market implications.

How important is it?

The earnings call could influence investor sentiment but lacks immediate significant developments.

Why Short Term?

Immediate market reactions expected post-earnings call based on results.

Related Companies

PACB
January 30, 2025 16:05 ET  | Source: PacBio MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/. Date: Thursday, February 13, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the “PacBio Q4 Earnings Call.” About PacBio Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Contacts Investors: Todd Friedmanir@pacb.com Media:pr@pacb.com

Related News